Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model

Gene Therapy

Volumn 18, Issue 10, 2011, Pages 969-978

  Tabata, K ^a   Kurosaka, S ^a   Watanabe, M ^a   Edamura, K ^a   Satoh, T ^a   Yang, G ^a,c   Abdelfattah, E ^a   Wang, J ^a,c   Goltsov, A ^a,c   Floryk, D ^a,c   Thompson, T C ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

gene modified cell therapy; Glipr1; macrophages; prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD40 ANTIGEN; GLIOMA PATHOGENESIS RELATED PROTEIN 1; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; GENE DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD40; ANTIGENS, CD80; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-12; INTERLEUKIN-6; KILLER CELLS, NATURAL; KINETICS; MACROPHAGES; MALE; MICE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

MUS;

EID: 80054052507     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.51     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl JMed 2004; 351: 1502-1512. (Pubitemid 39315317)
3. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
4. Che M, DeSilvio M, Pollack A, Grignon DJ, Venkatesan VM, Hanks GE et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int J Radiat Oncol Biol Phys 2007; 69: 1117-1123. (Pubitemid 47625839)
5. Thompson TC, Timme TL, Sehgal I. Oncogenes, growth factors and hormones in prostate cancer. In: Dickson RB, Salomon SD (eds). Hormones and Growth Factors in Development and Neoplasia. John Wiley and Sons: New York, 1998.
6. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J et al. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 2002; 22: 3345-3357. (Pubitemid 34453976)
7. Rich T, Chen P, Furman F, Huynh N, Israel MA. RTVP-1, a novel human gene with sequence similarity to genes of diverse species, is expressed in tumor cell lines of glial but not neuronal origin. Gene 1996; 180: 125-130. (Pubitemid 26417918)
8. Murphy EV, Zhang Y, Zhu W, Biggs J. The human glioma pathogenesis-related protein is structurally related to plant pathogenesis-related proteins and its gene is expressed specifically in brain tumors. Gene 1995; 159: 131-135.
9. Gingras MC, Margolin JF. Differential expression of multiple unexpected genes during U937 cell and macrophage differentiation detected by suppressive subtractive hybridization. Exp Hematol 2000; 28: 65-76. (Pubitemid 30047192)
10. Ren C, Li L, Yang G, Timme TL, Goltsov A, Ren C et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 2004; 64: 969-976. (Pubitemid 38176899)
11. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 2003; 14: 91-101. (Pubitemid 36418814)
12. Naruishi K, Timme TL, Kusaka N, Fujita T, Yang G, Goltsov A et al. Adenoviral vectormediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 2006; 13: 658-663. (Pubitemid 44264470)
13. Wang H, Thompson TC. Gene-modified bone marrow cell therapy for prostate cancer. Gene Therapy 2008; 15: 787-796. (Pubitemid 351627363)
14. Prill JM, Espenlaub S, Samen U, Engler T, Schmidt E, Vetrini F et al. Modifications of adenovirus Hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther 2011; 19: 83-92.
15. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 2003; 63: 7853-7860. (Pubitemid 37466719)
16. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60: 5857-5861.
17. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35. (Pubitemid 37328697)
18. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002; 62: 5069-5075. (Pubitemid 34984436)
19. Alleva DG, Askew D, Burger CJ, Elgert KD. Fibrosarcoma-induced increase in macrophage tumor necrosis factor alpha synthesis suppresses T cell responses. J Leukoc Biol 1993; 54: 152-160. (Pubitemid 23276405)
20. Hildenbrand R, Jansen C, Wolf G, Bohme B, Berger S, von Minckwitz G et al. Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. Lab Invest 1998; 78: 59-71. (Pubitemid 28074309)
21. Bonta IL, Ben-Efraim S. Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol 1993; 54: 613-626. (Pubitemid 24024234)
22. Oghiso Y, Yamada Y, Ando K, Ishihara H, Shibata Y. Differential induction of prostaglandin E2-dependent and-independent immune suppressor cells by tumor-derived GM-CSF and M-CSF. J Leukoc Biol 1993; 53: 86-92. (Pubitemid 23048053)
23. Alleva DG, Walker TM, Elgert KD. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages. J Leukoc Biol 1995; 57: 919-928.
24. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555. (Pubitemid 35223554)
25. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 2003; 23: 5015-5022. (Pubitemid 38182119)
26. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003; 10: 309-313.
27. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005; 104: 1246-1254. (Pubitemid 41278960)
28. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004; 99: 1667-1674. (Pubitemid 39237489)
29. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999; 79: 991-995. (Pubitemid 29082138)
30. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70: 5728-5739.
31. Hommes DW, Peppelenbosch MP, van Deventer SJ. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003; 52: 144-151. (Pubitemid 36020783)
32. Kim L, Del Rio L, Butcher BA, Mogensen TH, Paludan SR, Flavell RA et al. p38 MAPK autophosphorylation drives macrophage IL-12 production during intracellular infection. J Immunol 2005; 174: 4178-4184. (Pubitemid 40395996)
33. Salmon RA, Guo X, Teh HS, Schrader JW. The p38 mitogen-activated protein kinases can have opposing roles in the antigen-dependent or endotoxin-stimulated production of IL-12 and IFN-gamma. Eur J Immunol 2001; 31: 3218-3227. (Pubitemid 33100513)
34. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ et al. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 1999; 18: 1845-1857. (Pubitemid 29158528)
35. Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA et al. Glioma pathogenesisrelated protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 2008; 68: 434-443. (Pubitemid 351380069)
36. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004; 64: 6190-6199. (Pubitemid 39129421)
37. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996; 7: 515-523. (Pubitemid 26079062)
38. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Therapy 1999; 6: 338-349. (Pubitemid 29132337)
39. Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 2010; 38: D792-D799.
40. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C et al. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis 2000; 18: 429-438. (Pubitemid 32588624)
41. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989; 56: 917-930. (Pubitemid 19091004)
42. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927-1933. (Pubitemid 30207654)